NovoCure Ltd NVCR
News
Novocure's Premarket Application for Brain Metastases Treatment Otpune Mya Rejected by FDA
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure to Report Third Quarter 2026 Financial Results
Novocure Announces Upcoming Investor Events
